FDA Approves Stivarga as Treatment for Common Form of Liver Cancer
The U.S. Food and Drug Administration (FDA) approved the use of Stivarga (regorafinib) for the treatment of patients with hepatocellular carcinoma (HCC), a form of…
News
Radiation-delivering Microspheres Fight Liver Cancer as Well as Chemo, Clinical Trial Indicates
Radiation-delivering microspheres developed by Sirtex are as effective as Nexavar (sorafenib) chemotherapy against a liver cancer known as hepatocellular carcinoma (HCC), according to a Phase 3…
Exposure to High-Fat Diet in Womb and During Breastfeeding Linked to Liver Disease
A child exposed to a mother’s high-fat diet while in the womb and breastfeeding is at greater risk of developing non-alcoholic fatty liver disease (NAFLD)…
Fecal Transplant Improves Cognitive Malfunction Caused by Liver Disease, Study Finds
Transplanting fecal bacteria from a healthy person to someone who has a liver-connected brain impairment may be an effective way to treat the condition, known…
Enanta’s EDP-305 Therapy Shows Promise in Treating Non-Alcoholic Fatty Liver Disease
Candidate drug EDP-305 reduced fibrosis progression and improved non-alcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC) disease settings in several preclinical animal models, says…
NeuroVive’s NV556 Inhibits Liver Tumor Growth in Mice, Study Indicates
NV556 inhibited tumor growth in mice with a liver disease known as non-alcoholic steatohepatitis, or NASH, according to a study by its maker, NeuroVive Pharmaceutical AB.
‘Good Cholesterol’ Therapy CER-209 Enters Phase 1 Trial for NAFLD and NASH
Cerenis Therapeutics has initiated a Phase 1 clinical trial of CER-209 for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).
Ocera’s Therapy Candidate OCR-002 Prevented Cirrhosis Progression in NAFLD Animal Models
The latest preclinical results of Ocera Therapeutics’ ammonia scavenger OCR-002 showed that it can reduce fibrosis progression in animal models of non-alcoholic fatty liver…
Albireo Hosts NYC Breakfast to Discuss A4250 Therapy for Pediatric Liver Diseases
Boston-based Albireo Pharma hosted an April 13 breakfast presentation in New York that featured an overview of the company’s clinical programs as well as a talk by…
Galectin Plans to Present Data from Phase 2 NASH Cirrhosis Trial by Year’s End
Galectin Therapeutics’s lead drug GR-MD-02 may be a promising therapeutic approach to treat fibrosis in fatty liver disease — or non-alcoholic steatohepatitis (NASH) — based on results from…
Recent Posts
- Abnormal amino acid profile seen in biliary atresia infants after birth
- Our daughter’s PFIC diagnosis made us rethink drinking at Christmas
- Hepatitis D treatment combo granted new designations in US, EU
- Committee recommends seladelpar approval in EU for treating PBC
- Diet rich in omega-3 fatty acids may lower risk of ICP, scientists say